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Signal transducer and activator of transcription 1 (STAT1) is a latent 
transcription factor activated by Interferon gamma (IFNγ) receptor. The role of 
STAT1 in epithelial carcinogenesis remains poorly defined. Previous work 
performed in our lab showed that STAT1 was absolutely required for skin cancer 
promotion by chrysarobin using the multistage skin carcinogenesis model. A novel 
mechanism of skin tumor promotion involving IFNγ/STAT1 signaling was defined. 
Interestingly, Solar ultraviolet (SUV) radiation activated IFNγ/STAT1 pathway in a 
similar pattern as seen with chrysarobin. SUV treatment led to rapid 
phosphorylation of STAT1 on both tyrosine (Y701) and serine (S727) residues in 
epidermis. An increase of unphosphorylated STAT1 (uSTAT1) and interferon 
regulatory factor 1 (IRF1) were also observed and verified to be dependent on 
STAT1 activation. Further analyses demonstrated that the induction of 
phosphorylation of STAT1, and the increase of both IRF1 and uSTAT1 was 
dependent on intact IFNγ signaling. Quantitative PCR detected an increase of 
STAT1, IRF1 and other downstream targets of IFNγ/STAT1 axis including Cxcl9, 
Cxcl10, Cxcl11, PD-L1 and Cox2, which all depended on STAT1 activation. IFNγ 
receptor knockout mice displayed no activation of the IFNγ/STAT1 signaling 
viii 
pathway, weak activation of MAPK signaling and reduced myeloid cells influx into 
the dermis following exposure to SUV. CD3+ cells were determined to be the only 
source of IFNγ production in the epidermis following SUV treatment. Also, CD3+ 
cells were the primary cellular source of IFNγ production after CHRY treatment. A 
topical ointment application containing an oligonucleotide decoy was formulated to 
inhibit the activation of IFNγ signaling in the epidermis. Collectively, these findings 
clearly demonstrate that SUV activates the IFNγ/STAT1 signaling pathway in the 
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Chapter 1: Introduction 
1.1 Signal Transducers and Activators of Transcription 
 
Signal Transducers and Activators of Transcription (STATs) are a family of 
latent cytoplasmic transcription factors that transduce extracellular signals from the 
cell membrane to the nucleus [1]. Consisting of STAT1, Stat2, STAT3, STAT4, 
STAT5A/B and STAT6, STATs are involved in many different physiological 
regulatory events, including hematopoiesis, immunomodulation and development 
[2, 3]. On the other hand, aberrant Stat signaling has been associated with various 
pathological events, including oncogenesis. Of all the Stat family members, STAT1, 
STAT3 and STAT5 are found frequently to be constitutively activated in human 
tumors [4, 5]. STATs are activated by a variety of factors such as cytokines, growth 
factors, hormones and oncogenic signals. Following the binding of cytokines to 
their cognate receptors, STATs are activated by members of the janus activated 
kinase (JAK) family of tyrosine kinases. Once activated, they dimerize and 
translocate to the nucleus and modulate the expression of target genes (Fig. 1.1) 
[6-8]. JAK/STAT signaling is mechanistically simple with only a few principal 
components to translate an extracellular signal into transcriptional responses [9, 
10]. 
STATs exhibit a modular structure with six well-defined domains, including an 
N-terminal-conserved domain, a coiled-coil domain, a DNA binding domain, a 
linker region, an SH2 domain and a C-terminal transactivation domain (Fig 1.2). 
The SH2 domain, which is highly conserved among the STATs, plays a very 
important role in STAT signaling being critical for the recruitment of STATs to 
activated receptor complexes and for the interaction with JAK and Src kinases. 
Cytokine stimulation induces phosphorylation of tyrosine residues on the receptor 
that serve as docking sites for STATs via their SH2 domains. Once bound to the 
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receptor, all members of the STAT family become tyrosine phosphorylated in 
response to cytokine stimulation at a conserved C-terminal tyrosine, (e.g. Y701 for 
STAT1, Y705 for STAT3). Phosphorylation of this tyrosine appears to be achieved 
by growth factor receptors as well as by JAK and Src kinases, depending on the 
nature of the cell type and the ligand/receptor interactions. This form of 
phosphorylation induces STAT homodimerization and heterodimerization via the 
interaction of the phosphotyrosine residue of one STAT molecule with the SH2 
domain of another. The dimers then translocate into the nucleus by binding to 
importin-α and then induce target gene expression [11]. 
In addition to this canonical view of STAT signaling, it has now been firmly 
established that many if not all STAT proteins can exist as preformed dimers, which 
are unable to bind DNA, in the absence of the activating tyrosine phosphorylation 
[12]. However, the molecular interfaces that drive dimerization differ between 
individual STATs. The interaction of N-terminal domain has been found to be 
necessary for the dimerization of nonphosphorylated STATs [13].  
Previous investigations of Stat1 protein have identified three STAT1 protein 
forms: monomer, antiparallel unphosphorylated dimer and reciprocal pY-SH2 
parallel phosphorylated dimer (Fig 1.3). During the activation-inactivation cycle, 
STAT1 goes through conformational rearrangement from parallel to antiparallel 
structure [14-16]. The crystal structure for tyrosine phosphorylated STAT1 dimer 
bound to DNA has been determined [17]. The structure verified that the SH2 
domain necessary for dimerization is also involved in DNA binding. Moreover, 
some kinases can phosphorylate STAT1 at serine 727 (S727). This 
phosphorylation can occur independently of tyrosine phosphorylation and is not 
required for STAT1 translocation to the nucleus or for its binding to target gene 
promoters. However, it is essential for the full transcriptional activation [18]. 
In previous work performed in our laboratory, we established a critical role for 
3 
STAT3 in both chemical- and UVB-mediated epithelial carcinogenesis [19]. In a 
chemical-mediated epithelial carcinogenesis model, STAT3 was shown to be 
important during the initiation phase of epithelial carcinogenesis by regulating 
keratinocyte survival, including survival of bulge-region keratinocyte stem cells [20, 
21]. STAT3 was also shown to be important for the clonal expansion of initiated 
cells during tumor promotion by regulating key cell cycle progression proteins such 
as cyclin D1 and c-myc [20, 22]. Furthermore, STAT3 was found to also play a 
significant role in the progression of skin tumors via its ability to regulate genes 
involved in angiogenesis and epithelial-mesenchymal transition [23]. Furthermore, 
STAT3 was shown to play an important and similar role in UVB-mediated skin 
carcinogenesis [24, 25]. However, the exact role of other STATs in multistage 
























Figure 1.1 Key Steps of the JAK-STAT pathway 
Upon cytokine ligand binding to the cell surface receptors, JAK kinases 
phosphorylate the receptors, generating docking sites for the normally cytosolic 
STATs. After phosphorylated by JAK kinases, STATs dimerize and translocate to 
the nucleus and bind to the promoters of target genes to activate their transcription. 





























Figure 1.2 Structure of STAT proteins 
STATs harbor six domains, the N-terminal, coiled-coil, DNA-binding, linker, SH2 
and transactivation domains. The N-terminal and DNA binding domains cooperate 
in binding to the promoters of target genes.  

















Figure 1.3 Schematic of notable features of STAT1 protein structure 
The domains are N-terminal domain (ND), coiled:coil domain (CC), DNA-binding 
domain (DBD), linker domain (L), and SH2 domain (SH2). The ND is shown 
tethered to the CC through a flexible linker, and the residues C-terminal to –SH2 
include Y701, which is phosphorylated (red) when the molecule is activated. The 
C-terminal region is also flexible as indicated by the wavy black line. At the bottom 
of the figure are diagrams of the parallel and antiparallel structures. Notable is the 








1.2 Two Stage Carcinogenesis Model 
 
The classic two-stage, initiation-promotion model of skin carcinogenesis is a 
chemically-induced model of epithelial carcinogenesis that enables evaluation of 
three stages of tumor development, including tumor initiation, promotion and 
progression [27]. In standard protocols, topical application of a single 
subcarcinogenic dose of a carcinogen (e.g. 7,12-dimethylbenz(a)anthracene 
[DMBA]) induces irreversible DNA mutations in critical genes, including H-ras and 
K-ras, in keratinocyte stem cells in the bulge region of the hair follicles. Repeated 
topical treatment of a non-carcinogenic promoting agent, such as TPA or CHRY, 
can induce epidermal hyperplasia and cell proliferation. The initialed stem cells, 
during repetitive exposure to a promoting stimuli, have a selective growth 
advantage such that these cells undergo clonal expansion. The endpoint of the 
promotion stage in the mouse skin model is the formation of squamous papillomas, 
which are exophytic, noninvasive lesions consisting of hyperplastic epidermis 
folded over a core of stroma. The process of tumor progression occurs when 
papillomas convert to skin cell carcinomas (SCC). The SCCs that develop in this 
model are histologically very similar to human SCCs of the skin [reviewed in 
Epithelial Skin Cancer, The Molecular Basis of Cancer, 2015]. This model has 
been well characterized and bears relevance to human epithelial cancers, thereby 
providing an excellent paradigm for the study of mechanisms associated with 
multistage epithelial carcinogenesis (Fig. 1.4) [28]. 
Tumor promoting stimuli are very diverse in this model and include various 
chemicals such as phorbol esters (e.g. TPA), organic peroxides (e.g. benzoyl 
peroxide), anthrones (e.g. CHRY) and so on. Additionally, UV light, repeated 
abrasion, full thickness skin wounding, and certain silica fibers when rubbed on the 
skin all function as skin tumor promoting stimuli. Most tumor promoters are not 
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genotoxic but cause altered expression of genes whose products are associated 
with hyperproliferation, tissue remodeling, and inflammation. A number of changes 
in growth regulatory proteins and molecules occur during tumor promotion in the 
mouse skin model and are thought to stimulate a cascade of cell signaling events 
that alter cell proliferation and/or differentiation. The exact mechanisms for the way 
in which the different types of tumor promoters bring about the cellular, biochemical 
and molecular changes associated with the process of skin tumor promotion 
remains to be fully elucidated. For the phorbol ester type tumor promoters, the 
cellular receptor that initiates their actions is protein kinase C [29]. For compounds 
that break down to form reactive oxygen species (ROS) and other types of radical 
intermediates such as the anthrones (e.g. CHRY) and the organic peroxides (e.g. 
benzoyl peroxide), it is believed that they work by inducing oxidative stress that 




















Figure 1.4 Two-stage model of skin carcinogenesis in mice 
During initiation, topical application of a sub-carcinogenic dose of a mutagenic 
agent induces mutations in target genes in keratinocyte stem cells. Repeated 
topical application of a promoting agent begins 2 weeks after initiation and 
continues for the duration of the study. Papillomas begin to arise after ~6–12 weeks 
of promotion and a fraction begin to convert to SCC after ~20 weeks. 
Representative H&E stained sections of normal skin, hyperplastic skin, a papilloma 






1.3 Ultraviolet Radiation and Non-Melanoma Skin Cancer 
 
Wavelengths of both ultraviolet A (UVA 320-400 nm) and ultraviolet B (UVB 
280-320 nm) radiation have been implicated as carcinogens, though their methods 
of action are not the identical. The two wavelengths of radiation are able to 
penetrate to different depths of the skin and hence affect different cells in the 
epidermis and dermis: UVB radiation is mainly absorbed by epidermal components 
such as proteins or deoxyribonucleic acid (DNA), whereas UVA radiation 
penetrates deeply into the skin and reaches the lower epidermis and dermal 
fibroblasts. Other than tumorigenic predilection, UV radiation also disrupts 
keratinocytes in the skin epithelia, causing other immunological and inflammatory 
disorders [32]. 
The extent of their effect also varies, with UVB being described as the most 
carcinogenic among all types of solar radiation. UVB radiation’s main deleterious 
effect is DNA damage caused by its direct interaction with the molecule, while UVA 
radiation’s toxicity mainly comes from oxidative damage to skin cell components 
including DNA damage [33]. 
Nonmelanoma skin cancer is the most common cancer and consists of basal 
cell carcinoma and squamous cell carcinoma (SCC). Every year in the US, the 
incidence of nonmelanoma skin cancer excelled three million, leading to a 
significant economic burden for the society. Excessive exposure to sunlight 
radiation has been well documented to be the major cause of nonmelanoma skin 
cancer [34]. Because of its public health relevance and the need to understand the 
biologic impact of UV irradiation on the skin, there has been a long-standing 
interest in the mechanisms by which this form of radiant energy causes skin cancer. 
Observations from this line of investigation have led to a better understanding of 
UV-induced skin cancer specifically and, more broadly, of cancer in general.  
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The UVB range is generally found to be most effective in inducing skin cancer 
and most studies in the literature were conducted using lamps emitting mostly UVB. 
The signal transduction pathway and key molecules involved in the solar ultraviolet 
(SUV) -induced skin disorders including tumorigenesis are not yet completely 
elucidated. However, it has been clearly shown that UVA (320-400 nm) and UVB 
(280-320 nm) both function as initiators and promoters in carcinogenesis and 
possess immunosuppressive activity [35](thoroughly reviewed in IARC 
Monographs Vol55 and Vol100D). Moreover, on the surface of the Earth, UVA 
wavelengths are the most abundant (over 95%) in the sunlight UV spectrum. 
Therefore, the role of UVA wavelengths in skin tumorigenesis due to chronic sun 
exposure is worthy of further investigation (Fig. 1.6).  
A comparison of commercial SUV and UVB lamps are illustrated (Fig. 1.5). The 
UVB lamp emits a significant amount of UV in wavelengths shorter than 295 nm. 
These wavelengths are not found in sunlight, and for carcinogenesis induction, the 
UVB lamp can be unrealistically effective. To eliminate any unnatural results from 
the short-wavelength UV, the work in this thesis was performed using a light source 
generating both UVA and UVB by the ratio over 15:1 to mimic the UV emission of 
the sun (Ball, James C. 1995. A comparison of the UV-B irradiance of low-intensity, 
full-spectrum lamps with natural sunlight. Bulletin of the Chicago Herpetological 
Society. 30 (4):69-72.). This lamp was utilized by other researchers with success 
[36]. 
A number of contributing mechanisms to UV-induced skin tumorigenesis have 
been defined [37, 38]. For example, multiple signaling pathways may be activated 
in response to UVB including PKC, AhR, EGFR/ErbB, IL12, AP-1 and Cox-2 [29, 
39]. UVA wavelengths, which penetrate deeply into the skin, induce formation of 
ROS and oxidative stress in both epidermal keratinocytes and dermal fibroblasts 
[40, 41]. Using lamps (UVA-340) that closely mimicked sun UV emission, Zigang 
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Dong’s team showed that SUV–induced skin cancer relies upon activation of p38α, 

































Figure 1.5 Spectral irradiance of commercial UVA and SUV lamps versus 
natural sunlight 
Left graph shows the spectral energy distribution of the UVB lamp compared to 
sunlight. The UVB lamps showed a far greater disparity with sunlight bemuse of 
the far greater intensity of their range, while the SUV lamps (UV-A 340) were in 





























Figure 1.6 Sterenborg-Slaper action spectrum for ultraviolet-induced skin 
carcinogenesis in albino hairless mice 
Effectiveness is defined as the reciprocal of the daily dose at each wavelength that 
leads to tumors of 1mm diameter in 50% of animals in 265 days, relative to the 
corresponding value at the wavelength of maximal effectiveness. The 
effectiveness between 340 and 400 nm represents an average value for that 
wavelength range. 








1.4 IFNγ Signaling Pathway 
 
Interferons (IFNs) are pleiotropic cytokines that mediate anti-viral responses, 
inhibit proliferation and participate in immune surveillance and tumor suppression 
by inducing the transcription of a number of IFN-stimulated genes. The IFN family 
includes two main classes of related cytokines, type I IFNs and type II IFN. There 
are many type I IFNs including IFNα, IFNβ and many others. By contrast, there is 
only one type II IFN, IFNγ that is produced by activated T cells, natural killer (NK) 
cells and dendritic cells. Its origin can be traced back more than 450 million years 
ago and its structure is conserved among vertebrates [45]. Not surprisingly, a 
deficiency or mutant form of IFNγ has a wide range of effects including an elevated 
risk to viral and bacterial infections.  
IFNγ exerts its effects on cells by interacting with the specific IFNγ receptor 
that is composed of two subunits, IFNGR1 and IFNGR2 [46]. IFNγ receptor is 
expressed on surfaces of nearly all cells. JAK-STAT1 pathway plays a central role 
in IFNγ signaling [47]. Conventionally, IFNγ is associated with cytostatic/cytotoxic 
and antitumor mechanisms during cell-mediated adaptive immune response. 
However, more recent data have suggested a pro-tumorigenic role of IFNγ [48]. 
The IFNγ/STAT1 pathway has been extensively characterized as illustrated (Fig 
1.7). Many of IFN-γ-regulated genes are in fact transcription factors (e.g., IRF1), 
which are activated by IFN-γ and are able to drive regulation of the next wave of 
transcription. STAT1:STAT1:IRF-9 heterodimers, ISGF3, and IRF1 are able to bind 
to IFN-stimulated response element (ISRE) promoter regions in target genes to 
regulate transcription. IRF1 is also able to promote transcription of STAT1 through 
an unusual ISRE site (IRF-E/GAS/IRF-E).  
Ligand binding causes a conformational change in the IFNγR (IFNGR1; 
IFNGR2), such that the inactive JAK2 kinase undergoes autophosphorylation and 
16 
activation, which in turn allows JAK1 transphosphorylation by JAK2. The activated 
JAK1 phosphorylates functionally critical tyrosine on residue 440 of each IFNGR1 
chain to form two adjacent docking sites for the SH2 domains of latent STAT1. The 
receptor-recruited STAT1 pair is phosphorylated near the C terminus at Y701. 
Phosphorylation induces dissociation of a STAT1 homodimer from the receptor. To 
a lesser extent, IFN-γ signaling also produces STAT1:STAT1: IRF-9 and 
STAT1:Stat2:IRF-9 [IFN-stimulated gene factor 3 (ISGF3)] complexes. STAT1 
homodimers travel to the nucleus and bind to promoter IFN-γ-activation site (GAS) 

























Figure 1.7 The current paradigm of canonical IFNγ/STAT1 signaling pathway  
Binding of IFNγ to the extracellular portion of the JAK receptor propagates an 
intracellular signaling cascade via IRFs and STATs. These activated proteins are 
able to translocate into the nucleus to successfully activate transcription of 








1.5 Two Faces of STAT1 and IFNγ 
 
STAT1, as the first discovered member of the STAT family, serves as the 
principal mediator of both type I and type II interferon activation [50]. Due to 
impaired IFN signaling, STAT1 deficient mice are highly susceptible to both viral 
and bacterial infection [51]. Activated STAT1 (p-STAT1) has been associated with 
anti-tumorigenic or tumor suppressive properties by modulating key components 
of immune tumor surveillance [50, 52, 53], inducing pro-apoptotic regulators such 
as Fas/FasL and caspases and by regulating negative cell cycle proteins such as 
p21 and p27 [54-56] as well as negatively regulating angiogenesis [57]. Beyond 
immune surveillance, STAT1 limits tumor growth in a cell-autonomous fashion [58, 
59]. Studies have also revealed that the expression of STAT1 is frequently lost in 
various types of human cancer such as breast cancer, head and neck cancer, 
multiple myeloma and leukemia [60]. Researchers reported that following a single 
dose of the carcinogen methylcholanthrene, IFNγR-/- and STAT1-/- mice were highly 
susceptible to tumor formation compared 129/Sv controls. They also reported that 
STAT1 and p53 double knockout mice developed tumors more rapidly and with 
greater frequency than p53 single knockout mice [61]. STAT1-deficient mice 
spontaneously develop estrogen receptor α-positive luminal mammary carcinomas 
[62]. 
More recently, however, a pro-tumorigenic role of IFNγ/STAT1 has been 
demonstrated and discussed [48, 63, 64]. Constitutive activation of STAT1 and 
overexpression of IFNγ-related genes to breast cancers were associated with poor 
prognosis and activated STAT1 may confer resistance to radiation and adjuvant 
cancer therapy [65-69]. A pro-tumorigenic role of STAT1 has also been suggested 
in colon cancer [70, 71], esophageal squamous cell carcinoma [72], leukemia [73, 
74] and melanoma [75]. Emerging evidence has inspired the new concept that 
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IFNγ/STAT1 may exhibit both tumor suppressive effects as well as pro-tumorigenic 
effects depending on the tissue milieu and stimuli. 
Another interesting finding about IFNγ is that sustained low expression of IFNγ 
promoted tumor development whereas sustained high expression of IFNγ 
mediates significant antitumor effect. [76]. One intriguing underlying mechanism 
for IFNγ to promote tumorigenesis is by promoting tumor evasion of the immune 
system. PD-L1 and IDO are two downstream targets of IFNγ/STAT1 signaling 
pathway that can negatively regulate immune response in the local 
microenvironment. Merilino and his colleagues discovered that IFNγ links 
ultraviolet radiation to melanomagenesis in neonatal mice but not adult mice by 
promoting melanocytic cell survival/immunoevasion [77]. In the past few years, the 
importance of immune evasion, that exhibits dependence on IDO and PD-1/PD-
L1, in tumor development has been established in SCC [78, 79] and melanoma 
[80, 81].  
 
1.6 Rationale, Hypothesis and Specific Aims 
 
Using the two stage carcinogenesis model, we have recently discovered that 
STAT1 is absolutely required for tumor promotion in the epidermis by CHRY and 
the activation of STAT1 in the epidermis is dependent on IFNγ signaling pathway 
[82]. CHRY treatment led to upregulation of unphosphorylated STAT1 at later time 
points and upregulation of interferon regulatory factor 1 (IRF1) mRNA and protein, 
which was dependent on STAT1 activation. Further analyses demonstrated that 
topical treatment with CHRY upregulated IFNγ mRNA in the epidermis and that the 
induction of both IRF1 and STAT1 was dependent on IFNγ signaling. STAT1-/- mice 
were highly resistant to skin tumor promotion by CHRY. These studies not only 
define a novel mechanism associated with skin tumor promotion by the anthrone 
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class of tumor promoters (e.g. CHRY) involving upregulation of IFNγ signaling in 
the epidermis, but also add new evidence to support the positive correlation 
between the upregulation of IFNγ/STAT1 signaling pathway and skin cancer 
promotion. 
Induction of ROS is believed to play a significant role in the effects of SUV 
radiation on cellular processes including activation of cellular signaling pathways 
[83-85]. Thus, a common ROS-mediated mechanism may be shared by certain 
tumor promoters (e.g. CHRY and SUV) that activate multiple signaling pathways 
including the novel IFNγ/STAT1 pathway presented herein. 
In this study, I have tested the hypothesis that SUV activates STAT1 in 
keratinocytes via an IFNγ signaling pathway.  
Further study of this IFNγ/STAT1 signaling pathway in the context of skin 
homeostasis and in particular SUV-mediated skin carcinogenesis will likely lead to 
new targets and mechanisms for skin cancer prevention, especially for prevention 
of non-melanoma skin cancer.  
 
The specific aims of this study are: 
 
1. Specific Aim 1: Examine the response of epidermal keratinocytes to 
IFNγ treatment.  
Given that different types of cells respond to IFNγ uniquely; it is important to 
establish the in vitro response pattern of mouse keratinocytes after 
recombinant mouse IFNγ treatment.  
 
2. Specific Aim 2: Determine whether SUV (combination of UVA and UVB by 
a ratio of 15:1) activates IFNγ/STAT1 signaling in epidermis. 
In this aim, I will determine whether SUV induces IFNγ signaling activation in 
mouse epidermis. Mice deficient for STAT1 in epidermal keratinocytes or 
deficient for IFN receptor 1 (IFNγR1) will be used. A method that can prevent 
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the activation of IFNγ signaling pathway in the skin will also be developed. 
3. Specific Aim 3: Determine the cells in the epidermis that produce IFNγ in 
response to CHRY and SUV.  
The cellular source of IFNγ in the epidermis will be determined by employing 
IFNγ-reporter mice that carry an IRES-eYFP reporter cassette inserted 
between the translational stop codon and 3’ UTR/polyA tail of the IFNγ gene.  
  
22 
Chapter 2. Materials and Methods 
 
Animals 
STAT1-/- mice were a generous gift from Dr. David Levy (Kaplan Cancer Center, 
New York School of Medicine, NY). A functionally null STAT1 allele was generated 
by deleting a portion of the protein-coding region, resulting in the loss of a portion 
of the DNA binding domain. These mice were backcrossed for at least 5 
generations onto the FVB/N background. STAT1flox/flox mice were kindly provided 
by Dr. Mathias Müller and they were backcrossed for at least 5 generations onto 
the FVB/J background. The FVB background is a sensitive genetic background for 
two stage carcinogenesis experiments [86]. BK5.Cre transgenic mice were 
crossed with STAT1flox/flox mice to generate BK5.Cre x STAT1flox/flox mice, which are 
hereafter referred to as skin specific STAT1 deficient mice. Wild-type FVB mice, 
IFNγR1-/- mice and IFNγ-IRES-eYFP mice were purchased (The Jackson 
Laboratory). Genotyping was performed following standard protocol and primers 




Chrysarobin was synthesized in our lab and dissolved in acetone to obtain a 
concentration of 220 nmol. The mice were used for experimentation at 6-8 weeks 
of age. The dorsal skin of each mouse was shaved 2 days prior to treatment. For 
multiple treatment with chrysarobin, mice received application once weekly for four 
weeks and were sacrificed at various time points after the last treatment. Acetone 
vehicle (0.2 mL) was used as a control. 
SUV was emitted in a chamber containing 12 Sylvania F20T12/350BL lamps. 
The mice were shaved on their dorsal regions 2 days prior to treatment. During 
23 
treatment, each mouse was kept in individual enclosed cells with plastic cover 
allowing the transmission of SUV during the treatment. The enclosed mice were 
placed on a rotating platform that ensures even exposed doses. The mice were 
treated every other day for four times and each application took 4.5 hours to reach 
the dose of 28 J/cm2 UVA+1.9 J/cm2 UVB 
 
Cell Culture 
   Non-tumorigenic keratinocyte C50 cells were cultured in EMEM-3 medium with 
non-essential amino acids. Cells were starved for 24 hours in MEM-2 in the 
absence of all growth factors. Cells were pretreated with or without JAK1/JAK2 
inhibitor Ruxolitinib or JAK2 inhibitor AZD1480 (Selleck Chemicals) for 30min. In 
one protocol, the starvation medium that contains inhibitors was washed away 
before incubation with mouse recombinant IFNγ (BD Bioscience). In another 
protocol, stimulation with IFNγ started in the starvation medium that contained 
inhibitors. Cell were then lysed with cold RIPA buffer (Cell Signaling Technology) 
or RLT buffer (Qiagen) at various time points post stimulation. 
 
Western Blot 
After the mice were sacrificed by cervical dislocation, the dorsal skins were 
treated with a depilatory agent Nair (Church & Dwight Co.) followed by washing. 
Protease inhibitor cocktail, phosphatase inhibitor cocktail 2 and phosphatase 
inhibitor cocktail 3 (Sigma-Aldrich) were added to the RIPA lysis buffer (Cell 
Signaling Technology). After homogenization and centrifugation of the epidermal 
tissue lysate, the protein concentration of the supernatant was measured by Bio-
Rad protein assay system (Bio-Rad Laboratories). Epidermal lysates, cultured cell 
lysates or immunoprecipitates were separated on SDS-PAGE under reducing 
condition. The separated proteins were then transferred onto nitrocellulose 
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membranes (Bio-Rad Laboratories). Membranes were blocked for 1 hour in 3% 
bovine serum albumin at room temperature followed by overnight incubation with 
specific primary antibodies (Table 2.2) at 4°C. After washing with TBST containing 
0.1% Tween-20, blots were subjected to horseradish peroxidase-conjugated 
secondary antibodies (Table 2.2). After washing, the protein bands were visualized 
using a chemiluminescence detection kit (Pierce ECL Western Blotting Substrate). 
Quantitation was calculated by Image Studio Lite using Actin as the internal control. 
Primary antibodies against the following proteins were used: STAT1, STAT3, 
Akt, p38, Erk, JNK1/2, c-Jun, IRF1, NFkB, p-STAT1Y701, p-STAT1S727, p-STAT3Y705, 
p-SrcT416, JNK1/2T183/Y185, p-c-JunS73, p-p38T180/Y182, p-Erk1/2T202/Y204, p-AktT308, p-
AktS473, p-NFkBS536, Bcl-xL and survivin (Cell Signaling Technology); Cox2 
(Cayman); Actin (Sigma-Aldrich). 
 
Quantitative RT-PCR 
The epidermal tissue was homogenized in RLT buffer (Qiagen) before snap 
freezing. The total RNA was extracted using RNeasy Mini Kit (Qiagen) and residual 
genomic DNA was removed by treatment with RNase-free DNase I (Invitrogen). 
The concentration was determined by NanoDrop 2000c. 2 μg of total RNA was 
used to synthesize 20 μL of cDNA with High Capacity cDNA Kit (Applied 
Biosystems). The cDNA was diluted to 120 μL and 2 μL was used for each qPCR 
reaction. The reaction was performed using specific primers (Table 2.2) and iTaq 
SYBR green master mix (Bio-Rad Laboratories) on the Applied Biosystems ViiA 7. 
Relative gene induction was calculated using comparative Ct method with GAPDH 
used as an internal control. 
 
Immunofluorescence Staining 
The dorsal skins were fixed for 10 min in 4% paraformaldehyde before sinking 
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in 30% sucrose for another 10 min. Tissues were then embedded into FSC22 OCT 
(Surgipath Medical Industries) and snap frozen by liquid nitrogen. The 10 μm 
cryostat sections were permeabilized by 0.2% Triton-X100 and blocked by 1% 
bovine serum albumin and 10% serum. Sections were stained with specific primary 
antibody overnight at 4°C before washing with PBST. After incubation with 
fluorochrome (Alexa Fluor 488 or Alexa Fluor 594)-conjugated secondary 
antibodies for 2 hours at room temperature, the sections were washed and 
mounted using VECTASHIELD anti-fade mounting medium with DAPI (Vector 
Laboratories). Images were analyzed using an Olympus DP70 fluorescence 
microscope 




The excised dorsal skins were fixed in 10% neutral-buffered formalin. The 
formalin-fixed paraffin-embedded samples were sectioned and stained with 
hematoxylin & eosin, Ki67, cleaved caspase 3 and CD31 by the histology core at 
Dell Pediatric Research Institute, the University of Texas at Austin.  
 
Flow Cytometry Analysis 
Excised dorsal skins were subjected to a modified primary keratinocyte 
protocol [87]. After mechanically removing the subcutaneous fat, the skins were 
incubated in 5 mg/mL dispase (Life Technologies) at 37 °C for 30 min. 
Subsequently, the epidermis was peeled gently, incubated in 1 mg/mL collagenase 
IV (Sigma-Aldrich) at 37 °C for 30 min and strained through a 40 μm cell strainer 
to obtain a single cell suspension. The mononuclear cells including lymphocytes 
were separated from keratinocytes by Ficoll-Paque Plus (StemCell Technologies). 
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PE-Cy7 anti-CD3e (eBioscience) were used for extracellular staining and Zombie 
Violet Dye (Biolegend) was used for validation of cell viability. The samples were 
permeabilized and fixed by a Cytofix/Cytoperm Plus Kit (BD Pharmingen) before 
intracellular staining with APC anti-IFNγ or APC IgG1 Isotype control (BD 
Pharmingen). Spleenocytes were collected and stimulated with cell stimulation 
cocktail (eBioscience) containing TPA and ionomycin, and Brefeldin A (eBioscience) 
to prepare single color control. Brefeldin A was also added in every step during the 
isolation. The samples were finally analyzed by a BD LSRFortessa flow cytometry 
and FlowJo software. 
 
Oligonucleotides Application 
Double-stranded oligonucleotides were synthesized (Integrated DNA 
Technologies) from complementary single-stranded phosphorothioate bonded 
oligonucleotides. For decoy treatment of 50 nmol on one mouse, 1.45 g ointment 
was prepared by homogenizing 1240 mg Vaseline, 65 mg stearyl alcohol and 725 
nMole oligonucleotides in 145 μL TEN buffer (10 mM Tris and 1 mM EDTA and 150 
mM NaCl). All solutions and the ointment base, pestles, and mortars were pre-
warmed to 37°C before stirring for at 37°C for 15min during the mix. After the 
ointment cooled down, 1 mL of the ointment was painted topically for each 
application. Ointment was applied topically one day before chrysarobin treatment. 
STAT1 decoy    5'- CATGTTATGCATATTCCTGTAAGTG -3' 
STAT1 mutant   5'- CATGTTATGCAGACCGTAGTAAGTG -3' 
The bold letters denote phosphorothioate-bonded bases. 
 
Statistical Analyses 
For comparisons of quantitative protein expression, relative gene expression, 
epidermal thickness, labeling index and positive stained cells, the Mann-Whitney 
27 
U test was used. If not stated, significance was set at p<0.05. The statistical 



























Table 2.1 Primer sequences for genotyping 
 
 
Table 2.2 Primer sequences for RT-qPCR 
STAT1-/- Expected Fragments 
ST1 GAGATAATTCACAAAATCAGAGAG WT 142 bp 
ST2 CTGATCCAGGCAGGCGTTG KO 342 bp 
ST3 TAATGTTTCATAGTTGGATATCAT  
IFNγR1-/-  
oIMR6916 CTTGGGTGGAGAGGCTATTC WT 189 bp 
oIMR6917 AGGTGAGATGACAGGAGATC KO 280 bp 
oIMR0587 CCCATTTAGATCCTACATACGAAACATACGG  
oIMR0588 TTTCTGTCATCATGGAAAGGAGGGATACAG  
STAT1flox/flox   
69fwd GACATCTGGGGCAACTAGATA WT 522 bp 
54rev CTGGCATTTCTCCCTCACAC FL 357 bp 
77rev CTCACACCTACCCCTGTCG  
78fwd GGTGAAATTGCAAGAGCTGA  
BK5.Cre x STAT1flox/flox   
52fwd TTGGGCGTCACACATTACAT WT 482 bp 
54rev CTGGCATTTCTCCCTCACAC Floxed 830 bp 
71fwd CCAGAAGGCCACCTACAGAA  
BK5.Cre   
Crefwd CCATCTGCCACCAGCCAG Cre 281 bp 
Crerev TCGCCATCTTCCAGCAGG  
Gene Forward Primer  Reverse Primer 
Cxcl9 TCCTTTTGGGCATCATCTTC TTCCCCCTCTTTTGCTTTTT 
Cxcl10 CCGGGGTGTGTGCGTGGCTTCA TGCGAGCCTATCCTGCCCACGTG 
Cxcl11 AGGAAGGTCACAGCCATAGC CGATCTCTGCCATTTTGACG 
Cox2 CAAGACAGATCATAAGCGAGGA GGCGCAGTTTATGTTGTCTGT 
GAPDH CATGGCCTTCCGTGTTCCTA TGTCATCATACTTGGCAGGTTTCT 
IFNβ ACACTGCCTTTGCCATCCAAGAG TCCACCCAGTGCTGGAGAAATTG 
IFNγ CCTTCTTCAGCAACAGCAAGGC GGGTTGTTGACCTCAAACTTGGC 
iNOS ACCTTGTTCAGCTACGCCTT CATTCCCAAATGTGCTTGTC 
IRF1 AATTCCAACCAAATCCCAGG AGGCATCCTTGTTGATGTCC 
PD-L1 GTGAAACCCTGAGTCTTATCC GACCATTCTGAGACAATTCC 
STAT1 TCCCGTACAGATGTCCATGAT CTGAATATTTCCCTCCTGGG 
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Chapter 3: Examination of the IFNγ/STAT1 Signaling Axis in C50 
Keratinocytes 
 
It has been well documented that IFNγ can trigger various responses in 
different cell types [88]. C50 cells, a non-tumorigenic keratinocyte cell line was 
used to characterize how keratinocytes respond to IFNγ stimulation at molecular 
level (Fig. 3.1). With recombinant mouse IFNγ treatment, STAT1 was 
phosphorylated at Y701 very rapidly, with an observed increase of IRF1 beginning 
at 3h, followed by a prolonged increase of uSTAT1. Not quite consistent with the 
paradigm of IFNγ/STAT1 pathway, phosphorylation of STAT3 at Y705 was also 
observed. It was reported that p-Src was the kinase that phosphorylated STAT3 
following IFNγ treatment in mouse embryonic fibroblasts [89]. The level of p-Src 
after IFNγ treatment in our experiment did not increase until 6h post IFNγ 
stimulation. T Quantitative PCR has shown that Cxcl9/10/11 are the most 
responsive downstream targets following IFNγ treatment. Several pro-
inflammatory downstream targets that were commonly associated with tumor 
promotion, including iNos, Cox-2 and PD-L1, also increased. These findings 
reconciled our understanding of how keratinocytes respond to IFNγ stimulation.  
Though the importance of pSTAT3 in IFNγ pathway is unknown, we have 
discovered that JAK2 was responsible for the phosphorylation of both STAT1 and 
STAT3 (Fig. 3.2). Incubation with both JAK1/2 inhibitor Ruxolitinib and JAK2 
inhibitor AZD1480 completely prevented the phosphorylation of STAT1 and 
STAT3, and the increase of downstream target IRF1, suggesting that JAK2 is the 
primarily kinase in IFNγ pathway that phosphorylates STAT1 and STAT3. 
Incubation with EGFR inhibitor AG490 did not prevent the phosphorylation of 
STAT1 and STAT3 by IFNγ treatment, indicating that this pathway circumvents 
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signaling through EGFR kinase (Data not shown). Pretreatment with JAK2 
inhibitor for 30min significantly delayed the onset and extent of STAT3 
phosphorylation, and to a lesser degree, STAT1 phosphorylation, indicating that 
JAK2 preferably phosphorylates STAT1 in the IFNγ signaling pathway. 
Immunoprecipitation data showed low level formation of pSTAT1:pSTAT3 
heterodimer although the molecular consequences of that heterodimer are 








Figure 3.1 Examination of the IFNγ/STAT1 signaling pathway in C50 keratinocytes with 
IFNγ treatment 
Serum starved C50 non-tumorigenic keratinocytes were stimulated with recombinant mouse 













Figure 3.2 Evaluation of the effect of JAK inhibitors incubation or pretreatment on 
IFNγ/STAT1/IRF1 signaling axis in C50 keratinocytes with IFNγ treatment 
Upper: Serum starved C50 non-tumorigenic keratinocytes were incubated with 
JAK1/JAK2 inhibitor Ruxolitinib or JAK2 inhibitor AZD1480 for 30min, and then stimulated 
with recombinant mouse IFNγ (100 ng/mL).  
Lower: Serum starved C50 non-tumorigenic keratinocytes were pretreated with 
JAK1/JAK2 inhibitor Ruxolitinib or JAK2 inhibitor AZD1480 for 30min, and then stimulated 
with recombinant mouse IFNγ (100 ng/mL) in fresh medium without the presence of 
inhibitors. 
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Chapter 4. Examination of the IFNγ/STAT1 Signaling Pathway 
Following SUV Treatment 
4.1 SUV Activated IFNγ/STAT1 Pathway in Wildtype Mice. 
 
Previous experiments with CHRY have established a novel mechanism of skin 
tumor promotion. Investigations of the SUV activated IFNγ/STAT1 pathway may 
help us to evaluate our hypothesis that this mechanism is shared by more than 
one chemical tumor promotor, and that it has relevance to human skin cancer.  
A time course of FVB/J mice with SUV treatment was conducted. Here, we 
clearly demonstrated that the IFNγ/STAT1 pathway was activated in adult mice 
after SUV treatment (Fig. 4.1). Phosphorylation of STAT1 at Y701 increased at 3h 
and gradually decreased after 12h following SUV treatment. A robust induction of 
uSTAT1 and IRF1 was also observed. qPCR data suggested that, compared to the 
untreated basal level, IFNγ mRNA levels increased by 3 folds in the epidermis at 
1h following SUV treatment. The pattern of IFNγ pathway activation in the 
epidermis after SUV treatment was similar to what we have observed in vitro with 





























Figure 4.1 Examination of the IFNγ/STAT1/IRF1 signaling pathway in the 
epidermis of FVB/J mice with SUV treatment 
FVB/J female mice were shaved and treated with SUV every other day for a total of 
four doses. Epidermal protein and RNA samples were collected at indicated time 
points after the last SUV treatment. indicates value between experimental group 
and control group was significantly different by Mann-Whitney U-test (p<0.05). 
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4.2 The Activation of IFNγ Pathway by SUV Depended on STAT1 Activation 
and Intact IFNγ Receptor. 
 
Multiple treatments of SUV administrated every other day for a total of 4 
treatments led to phosphorylation of STAT1 at both Y701 and S727 at 6h, and an 
increase of IRF1 and uSTAT1, which all depended on a functional STAT1 as these 
changes were not observed in STAT1-/- mice (Fig. 4.2). All of these events 
suggested that IFNγ/STAT1 was activated in a similar manner in the epidermis as 
we have observed following treatment with CHRY [82]. 
To further test our hypothesis, IFNγR1-/- mice were utilized. As shown in Figure 
4.3, a functional IFNγ receptor was required for the phosphorylation of STAT1 Y701 
and the induction of IRF1 and uSTAT1 induced by SUV. mRNA levels of other 
downstream targets of this pathway were evaluated by qPCR and were found to 
be consistent with the changes at protein levels (Fig. 4.3). Chemokines, such as, 
Cxcl9, Cxcl10 and Cxcl11, were dramatically increased following SUV radiation 
and were also dependent on an intact IFNγR1 for maximal expression. An increase 
of Cox2 expression after SUV treatment was observed but did not appear to be 






















Figure 4.2 Analysis of STAT1 phosphorylation and IRF1 protein level 
following SUV treatment in STAT1 deficient mice 
Female WT and STAT1-/- (4/group) were shaved and treated with SUV every 
other day for a total of four doses. Epidermal protein samples were collected at 
indicated time points after the last SUV treatment. 
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Figure 4.3 Analysis of the IFNγ/STAT1 signaling in the 
epidermis of IFNγR1 deficient mice with SUV treatment 
Female WT and IFNγR1-/- mice (4/group) were treated with 
SUV and samples were collected at indicated time points. The 
normalized protein value represents an average of three 
independent experiments. The mRNA value is representative 
of three independent experiments.  indicates values 
between experimental and corresponding control groups were 
different by Mann-Whitney U-test (p<0.05). 
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4.3 The Impact of STAT1 Deficiency in Keratinocytes on IFNγ Pathway 
Induction  
 
To further explore the role of IFNγ/STAT1 signaling in the epidermis, we 
employed keratinocyte specific STAT1 knockout mice. For these studies, BK5.Cre 
x STAT1flox/flox mice, where STAT1 is specifically knocked out in keratinocytes, were 
used. Initial experiments with four doses of CHRY treatment did not induce the 
activation of IFNγ pathway (Fig. 4.4) in BK5.Cre x STAT1flox/flox mice. This 
corroborates previous results using STAT1-/- mice from our laboratory and provides 
verification of the establishment of BK5.Cre x STAT1flox/flox mice model. In addation, 
these data strongly supported the conclusion that activation of this pathway in the 
keratinocytes was responsible for the obsereved effects. Notably, the production 
of IFNγ mRNA in the epidermis after chrysarobin treatment was not dependent on 
the presence of STAT1.  
We next evaluated the effect of keratinocyte specific deletion of STAT1 on SUV 
induced IFNγ/STAT1 signaling. Compared to the data with STAT1-/- mice (Fig. 4.2), 
essentially identical results were obtained using BK5.Cre x STAT1flox/flox mice. 
These findings were validated at the transcriptional level by reverse quantitative 
PCR (Fig. 4.5). These data strongly suggested that SUV activated IFNγ/STAT1 








Figure 4.4 Examination of the IFNγ/STAT1/IRF1 signaling axis in response to CHRY 
treatment using mice with epidermal specific deletion of STAT1 
STAT1flox/flox and BK5.Cre.STAT1flox/flox mice (4/group) received 220nmol chrysarobin 
weekly for four weeks. Epidermal lysates were prepared at the indicated time points for 
protein and mRNA analyses.  indicates values between experimental and 
corresponding control groups were significantly different by Mann-Whitney U-test 




Figure 4.5 Examination of the IFNγ/STAT1/IRF1 signaling axis in response to SUV 
treatment using mice with epidermal specific deletion of STAT1 
STAT1flox/flox and BK5.Cre.STAT1flox/flox mice (4/group) were treated with SUV every other 
day for a total of four doses and epidermal samples were collected at indicated time 
points. The normalized protein value represents an average of from three independent 
experiments. The quantitative mRNA value is a representative (4-6 mice/group) of three 
independent experiments. indicates values between experimental and corresponding 
control groups were significantly different by Mann-Whitney U-test (p<0.05). 
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Chapter 5. Inhibition of IFNγ Pathway by Topical Treatment of 
Oligonucleotides 
 
Decoy oligonucleotides are short double-stranded DNA molecules that 
penetrate the skin rather easily, presumably due to active transcellular transport. 
When targeting transcription factors, they mimic the genomic binding site of the 
target transcription factor so that its activity is blocked and, thereby, the expression 
of its target genes [90]. When targeting mRNA expression, antisense 
oligonucleotides hybridize with a target mRNA to downregulate gene expression 
via a RNase H-dependent mechanism [91, 92].  
To target the transcription factor STAT1, a decoy strategy has been developed 
using oligonucleotides containing a gamma-activated site (GAS) motif for specific 
binding [93]. A Vaseline-based ointment was formulated for topical delivery of 
oligonucleotide decoys and stearyl alcohol was added as an emulsifier. 
The decoy was applied in doses of 25 nmol and 50 nmol. Mutant decoy in 
which the consensus-binding GAS element has been mutated was prepared in 50 
nmol. Topical treatment with decoy inhibited the activation of IFNγ pathway in a 
dose dependent manner (Fig. 5.1). Notably, decoy treatment substantially inhibited 
the induction of phosphorylated STAT1 and IRF1 after CHRY application, 
suggesting a mechanism of dephosphorylation associated with decoy 
oligonucleotides. 
Interestingly, the induction of phosphorylated STAT3 (Fig. 5.1) and its 
downstream targets, including Bcl-xL and Survivin (Fig. 5.2), were not affected by 



















Figure 5.1 STAT1 decoy oligonucleotides mediated inhibition of IFNγ signaling 
pathway in FVB/J mice epidermis after challenge with CHRY 
Female FVB/J mice (4 mice/group), 8 weeks old, were topically treated with ointment 
containing different doses of STAT1 decoy or mutant decoy 24h before challenge with CHRY. 
The treatment was applied weekly for three successive weeks. Six hours after the last CHRY 



















Figure 5.2 Specificity of STAT1 decoy oligonucleotides 
STAT1 decoy oligonucleotides did not affect the induction of STAT3 downstream targets 
after CHRY treatment. 
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Chapter 6. The Cellular Source of IFNγ Production 
 
Our data demonstrated that both CHRY and SUV treatment led to the 
upregulation of IFNγ mRNA and the activation of IFNγ pathway in the epidermis. 
Consequently, the cellular source of IFNγ was interrogated.  
There is evidence that IFNγ may be produced by T cells, natural killer cells and 
natural killer T-cells. Also, there is considerable complexity in the immune cell 
content of the skin. The relative contribution and function of resident versus 
migrating cells still remains unclear in many instances. 
We employed IFNγ reporter mice in this aim. The "interferon-gamma reporter 
with endogenous polyA transcript" allele has an IRES-eYFP reporter cassette 
inserted between the translational stop codon and 3' UTR/polyA tail of the IFNγ 
gene. Thus, the bicistronic IFNγ-IRES-eYFP mRNA is under control of the 
endogenous IFNγ promoter/enhancer regions with proper regulation defined by 
the endogenous 3' UTR and polyA tail. 
The skin was fixed at 1 hour after SUV treatment and double 
immunofluorescence staining showed that CD3+ cells were the source of IFNγ in 
the epidermis and dermis (Fig. 6.1). It was also observed that SUV greatly induced 
epidermal hyperplasia and an infiltration of CD3+ cells into the dermis. However, 
the number of CD3+ cells in the epidermis significantly decreased with SUV 
treatment. 
With chrysarobin treatment, CD3+ cells decreased in the epidermis while an 
infiltration of CD3+ cells in to the dermis was observed. CD3+ cells are the main 
source of IFNγ in the hyperplastic epidermis (Fig. 6.2 CHRY1st) but not the only 
source (Fig. 6.2 CHRY2nd). In the dermis, however, compared with acetone group, 
there was a significant increase of both eYFP+ and CD3+ cells following 
chrysarobin treatment. Most of the eYFP+ cells were not CD3+.  
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By using flow cytometry, we have confirmed that, in the epidermis, chrysarobin 
treatment led to the production of IFNγ from both CD3+ and CD3- cells by the ratio 



























































Figure 6.1 Identification of IFNγ-producing CD3+ cells following SUV treatment 
Female IFNγ reporter mice, 6 weeks old, were treated with SUV every other day for a total of 
four doses. Skin was collected at 1h following the last treatment. eYFP, CD3 and DAPI triple 
immunofluorescence staining were performed using 4% PFA fixed frozen sections. 
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Figure 6.2 Identification of IFNγ-producing CD3+ cells following CHRY treatment 
In this study, female IFNγ reporter mice, 6 weeks old, were treated with 220 nmol 
chrysarobin or acetone weekly for four successive weeks. Skin was harvested at 6h 
following the last treatment. eYFP, CD3 and DAPI triple immunofluorescence staining were 











Figure 6.3 Dual fluorescence flow cytometry analysis of IFNγ-producing CD3+ cells 
following CHRY treatment 
Six female FVB/N mice, 6-8 weeks old, were treated with 220 nmol chrysarobin weekly for 
four successive weeks. Skin was harvested at 4h post the last treatment. Epidermal cell 
suspensions were enriched for mononuclear cells (mostly lymphocyte), which were subjected 
to extracellular staining of PE-Cy7 conjugated CD3 antibody and intracellular staining of APC 
conjugated IFNγ antibody or isotype control. 
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Chapter 7. The Biological Impact of the SUV-induced IFNγ 
Signaling Activation 
Mitogen-Activated Protein Kinase (MAPKs) play a major role in SUV-induced 
skin cancer development [94]. The pattern of SUV-induced MAPK activation has 
also been characterized [95]. In this study, we tested the impact of the IFNγ 
receptor deficiency on SUV-induced MAPK activation. 
After SUV treatment on WT mice, p-p38T180/Y182, p-JNK1/2T183/Y185 and p-c-
JunS73 all increased at 6h and 24h. p-Erk1/2T202/Y204, however, decreased after 
treatment (Fig 7.1). These findings are in line with the published in vivo data using 
similar treatment conditions [42]. For all these targets, IFNγR1-/- mice respond to 
SUV treatment in the same pattern, but to a lesser extent, suggesting crosstalk 
between SUV-induced IFNγ signaling and SUV-induced MAPKs activation. 
Cxcl9, Cxcl10 and Cxcl11 are chemokines that are known to bind a common 
Cxcr3 receptor on both lymphoid and myeloid cells and recruit these cells to the 
inflammatory sites. In our study, SUV-induced IFNγ signaling activation greatly 
elevated the mRNA levels of Cxcl9, Cxcl10 and Cxcl11 in the skin. It was 
reasonable to speculate that the infiltration of immune cells caused by SUV 
treatment is, at least partly, dependent on the activation of IFNγ pathway and the 
secretion of Cxcr3 ligands. Histological analyses using a pan-myeloid marker 
CD11b revealed a decrease of myeloid cells influx in IFNγR1-/- mice compared to 
that in WT mice after SUV treatment (Fig. 7.2). This difference was most evident 
at 6h, the earliest time point examined. 
There was no difference in epidermal thickness between WT and STAT1 
conditional knockout mice following multiple SUV treatment. Proliferative index 
showed that, at 24h post last SUV treatment, WT mice had slightly higher 
proliferation than STAT1 conditional knockout mice (Fig 7.3). However, this 










Figure 7.1 Examination of the MAPK signaling in the epidermis of IFNγR1 
deficient mice with SUV treatment 
Female WT and IFNγR1-/- mice (4/group) were treated with SUV every other day for 
four treatments and epidermal samples were collected at indicated time points after 




















Figure 7.2 IFNγR1 deficient mice display a reduced influx of myeloid cells after SUV 
treatment 
Female WT or IFNγR1-/- mice were treated with SUV every other day for four doses. 
Formalin-fixed paraffin-embedded skin tissues were sectioned and stained with CD11b. 






Figure 7.3 Comparisons of epidermal thickness and labeling index in WT and STAT1 
skin conditional knockout mice following SUV treatment 
STAT1flox/flox or BK5.Cre STAT1flox/flox mice (4/group) were treated with SUV every other day 
for four doses and terminated 24h following the last treatment. Formalin-fixed paraffin-
embedded skin samples were sectioned for histological analyses. Epidermal thickness was 
measured on Hematoxylin and Eosin stained sections and labeling index was assessed by 
Ki67 stained sections. 
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Chapter 8. Discussion 
In this study, we examined the possibility that SUV, a combination of UVA and 
UVB in a ratio close to that of sunlight, can activate the IFNγ/STAT1/IRF1 signaling 
axis in the epidermis of mice. 
Initially, we investigated the activation pattern of IFNγ signaling pathway in 
mouse non-tumorigenic keratinocytes. C50 cells were treated with recombinant 
IFNγ in a time course experiment. IFNγ led to rapid phosphorylation of both STAT1 
and STAT3 at 15 min. IRF1 and uSTAT1 proteins increased at later time points 
evaluated and uSTAT1 were sustained until 24h. These changes in protein levels 
were associated with changes in mRNA levels. Among all the downstream targets 
of this signaling tested, Cxcl9 and Cxcl10 mRNA showed the most substantial 
increase (>1000 fold). Cxcl9, Cxcl10 and Cxcl11 have a common receptor, CXCR3, 
which is expressed primarily on activated T lymphocytes and NK cells, and some 
epithelial cells. CXCR3 and its ligands form a signaling axis that has been 
suggested to promote skin tumorigenesis [96, 97]. Cox2 and iNOS, which are 
commonly associated with inflammation and cancer development, also increased 
at 3h post IFNγ treatment of C50 cells. PD-L1, which promotes immune evasion 
also increased following IFNγ stimulation. These findings together establish a well-
defined pattern of how non-tumorigenic keratinocytes respond to IFNγ. 
Interestingly, STAT3 was also rapidly phosphorylated in C50 cells in response 
to IFNγ treatment. Qing and Stark [98] suggested that Src family kinases were 
responsible for the phosphorylation of STAT3 in mouse embryo fibroblasts upon 
IFNγ treatment. However, in our experiments with C50 keratinocytes p-Src levels 
did not increase until 6h post IFNγ stimulation while STAT3 phosphorylation at 
Y705 occurred within 15 min. Incubation of C50 cells with both JAK1/2 and JAK2 
inhibitors completely prevented the phosphorylation of STAT3 as well as STAT1, 
suggesting that JAK2, upon IFNγ stimulation, was the kinase that phosphorylates 
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STAT1 and STAT3. However, the importance of STAT3 phosphorylation here 
needs further investigation in terms of cellular response to IFNγ. 
Earlier studies in our lab demonstrated that treatment with CHRY, a non-
phorbol ester skin tumor promoter, led to skin tumor promotion in the two stage 
carcinogenesis model by a novel mechanism involving IFNγ/STAT1 signaling [82]. 
In the current study, utilizing IFNγ reporter mice, we further discovered that CD3+ 
cells in the epidermis were the main source of IFNγ production after CHRY 
treatment. Immunohistological analyses identified some CD3- that also contributed 
to IFNγ production and flow cytometry data showed that these cells represented 
approximately one third of the IFNγ-producing cells. These CD3- cells remain to 
be characterized. These data confirmed our hypothesis that CHRY treatment leads 
to increased production of IFNγ in immune cells resident in the epidermis. 
Skin specific STAT1 deficient mice were also developed for the current study. 
STAT1 was knocked out in keratinocytes expressing Cre under control of the 
bovine keratin 5 (BK5) promoter. Similar to our previous experiments with STAT1 
total body knockout mice, CHRY treatment activated IFNγ/STAT1/IRF1 signaling, 
which was dependent on the presence of STAT1. In keratinocyte specific STAT1 
deficient mice, the increase of IRF and uSTAT1 in epidermis was substantially less 
than in the control group (1:3 and 1:9, respectively). This difference was not due 
to possible interference with IFNγ production from knocking out STAT1 as qPCR 
data revealed a very similar pattern of IFNγ mRNA increase at 6h post CHRY 
treatment in both STAT1flox/flox (Wildtype) and BK5.Cre.STAT1flox/flox mice. The 
detectable weak activation (Fig 4.4) could be explained by the varying efficiency of 
CRE-loxP system. Perhaps more significantly, other types of cells (e.g. epidermal 
dendritic cells) that reside in the epidermis and retain functional STAT1 in the 
epidermis of BK5.Cre.STAT1flox/flox would respond normally to IFNγ.  
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These data using CHRY have refined the novel mechanism of skin tumor 
promotion involving IFNγ/STAT1 signaling. CHRY treatment leads to the 
production of IFNγ in the epidermis, mostly by CD3+ cells. In the two stage 
carcinogenesis model, activation of IFNγ/STAT1 signaling, including rapid 
phosphorylation of STAT1 and subsequent induction of IRF1 and uSTAT1, in skin 
keratinocytes mediates the skin tumor promotion of CHRY. During the tumor 
promotion by CHRY, STAT1 is absolutely required as previously reported by our 
laboratory [82]. 
To bring human relevance to this novel mechanism, we tested the hypothesis 
that SUV activates the IFNγ/STAT1/IRF1 signaling axis in the epidermis. A time 
course study demonstrated an IFNγ signaling pattern very similar to what we have 
observed in C50 cells in vitro with recombinant IFNγ stimulation. In an initial 
experiment, qPCR data showed that IFNγ mRNA peaked at 1h following the last 
of four SUV treatments. In experiments using keratinocyte specific STAT1 
knockout mice, we demonstrated that the induction of downstream targets 
including Cxcl9, Cxcl11, and IRF1 exhibited dependence on the presence of 
STAT1. Also, it was evident that, in IFNγR1-/- mice, SUV did not induce the 
activation of IFNγ signaling and its downstream components, suggesting that IFNγ 
is the primary driving force for the increase of IRF1, STAT1, Cxcl9, Cxcl10 and 
Cxcl11 in the epidermis after SUV treatment.  
IFNγ was shown to regulate Cox2 expression in our in vitro experiments (Fig. 
3.1) and in normal human epidermal keratinocytes [99]. The importance of Cox2 
in UV-induced skin cancer has been previously validated by a number of research 
teams [100-102]. A variety of pathways modulate UV-induced Cox2 expression 
[103, 104]. However, in our experiments, both WT and IFNγR1-/- mice showed a 
dramatic increase of Cox2 mRNA following SUV treatment, indicating that IFNγ 
signaling was not the primary regulator of UV-induced Cox2 expression.  
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Given that SUV consists of UVA and UVB by the ratio of 15:1, it’s intriguing to 
investigate the independent contribution of UVA and UVB in the induction of IFNγ 
signaling pathway in the epidermis. UVA is the major component of sunlight and is 
the major component in our SUV treatments, however on a photon-to photon basis, 
UVB has more energy than UVA. In a preliminary study, FVB/J mice were treated 
with 20 J/cm2 UVA every other day for three treatments and there was little or no 
activation of IFNγ signaling (data not shown). Still, this cannot completely rule out 
the possibility that UVA contributed to the SUV-induced IFNγ under other treatment 
conditions. Merilino et al. found that IFNγ mRNA was elevated in the skin of 
neonatal mice following UVB treatment, which led to melanomagenesis [77]. 
Reeve et al., however, showed that IFNγ was involved in photoimmunoprotection 
by UVA radiation and that radiation with high UVA/UVB ratio upregulated the 
expression of cutaneous IFNγ [105, 106]. UVA irradiation, but not UVB, resulted in 
increased epidermal IFNγ expression peaking earlier at 1 day in hairless mice 
[107]. Future mechanistic study requires further analyses of untreated, UVA, UVB 
and SUV groups for a comprehensive comparison.  
The data using IFNγ reporter mice represent the first report that CD3+ cells 
are the cellular source of IFNγ production upon SUV treatment. Unlike the findings 
of CHRY studies where some of the IFNγ producing cells in the epidermis were 
CD3- cells, CD3+ cells were the only cells that appeared to produce IFNγ in the 
epidermis following SUV treatment based on immunofluorescence. We found that 
the CD3+ positive cells identified in the epidermis of the control group were very 
abundant and displayed a profound dendritic morphology while CD3+ cells in the 
hyperplastic epidermis after multiple treatment were relatively sparse and did not 
adopt a dendritic shape. A variety of immune cells are present in normal skin, 
including subsets of dendritic cells and lymphocytes, as well as macrophages, 








Figure 8.1 Skin structure and immune cell types found in skin 
Multiple immune cells types are found within skin, including Langerhans cells, 
dendritic epidermal γδ T cells (DETC), and memory αβT cells (TRM) in the 










cell types and population before and after SUV treatment, which has been reported 
in the literature [109]. Since CD3 is a pan T cells marker, the CD3+ cells that 
produced IFNγ can be further characterized. Earlier study in our lab demonstrated 
that single CHRY treatment caused a significant induction of IFNγ downstream 
targets (i.e. STAT1 and IRF1) at 6h. We believe that resident immune cells in the 
epidermis were responsible for the production of IFNγ because, at less than 6h 
post single treatment, there would not be enough time for cells in the dermis to 
migrate into epidermis, and then produce this cytokine. Dendritic γδ T cells have 
very high abundance in the epidermis and can contribute to immune response. 
They also form a prominent network in the skin in mice where they appear to 
monitor the integrity of the epidermal layer [110, 111]. In an in vitro experiment 
using an established protocol (TPA, ionomycin and Brefledin A) to stimulate IFNγ 
production in splenocytes, γδ T cells were competent at producing IFNγ (data not 
shown). Together with reports from other laboratories [112], we speculate that this 
CD3+ cell population can produce IFNγ following SUV treatment. Other T cells (i.e. 
resident memory T cells), though they reside at lower abundance in the epidermis, 
could also serve as the cellular source of IFNγ. Further studies will be required to 
distinguish these possibilities. 
The biological impact of the SUV-induced IFNγ/STAT1/IRF1 signaling axis 
activation remains to be fully determined. The data we obtained from mice of 
different genetic backgrounds demonstrated a similar activation pattern at both 
protein level and mRNA level. We found that MAPK activation, which was reported 
to play a role in SUV-induced skin cancer [94], was reduced in IFNγR1-/- mice 
compared to that in WT mice. Also, after multiple SUV treatments, IFNγR1-/- mice 
displayed less myeloid cells infiltration into the dermis. Further analyses 
demonstrated that multiple SUV treatment led to increased epidermal thickness in 
both WT and STAT1 conditional knockout mice to a similar extent but WT mice has 
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slightly higher labeling index compared to STAT1 conditional knockout mice. This 
finding is similar to what we have observed in previous CHRY studies. Whether 
the IFNγ signaling pathway plays a role in SUV-induced skin cancer remains to be 
determined. Future studies are aimed at defining the role of IFNγ/STAT1 signaling 
axis in skin carcinogenesis by SUV. 
Finally, we successfully developed a topical ointment application that inhibits 
STAT1 activation and transcriptional activity (i.e. STAT1 decoy; Fig 5.1). The 
successful formulation of this STAT1 decoy ointment provides us a useful 
experimental tool with substantial efficacy. The precise topical application may 
greatly limit the potential side effects to the whole body. One remaining issue is 
that mutant STAT1 decoy also had an inhibitory effect on IFNγ/STAT1 signaling 
pathway with a much lower efficiency compared to STAT1 decoy at the same dose. 
We suspect that mutant decoy still interacted with phosphorylated STAT1. A 
scrambled control decoy can be more suitable in future studies to eliminate any 
remaining affinity associated with the mutant decoy and to further define specificity. 
The recurrent interaction of skin with sunlight is an intrinsic constituent of 
human life, and exhibits both beneficial and detrimental effects. The robust 
architectural framework of skin conceals remarkable mechanisms that operate at 
the interface between the surface and environment. The data here demonstrate 
that SUV induces IFNγ production from the CD3+ cells in the epidermis, and IFNγ 
activates IFNγ/STAT1/IRF1 signaling axis in epidermal keratinocytes, which is 
completely dependent on STAT1. This discovery bridges our previous finding of a 
novel mechanism for skin tumor promotion to solar irradiation, the major cause of 
human skin cancer. It also provides further avenues for future studies. The roles of 
IFNγ/STAT1 signaling pathway in SUV-induced skin carcinogenesis, skin disorder 
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